Bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high risk groups
Bone turnover is the process of bone breakdown and renewal; under normal circumstances, these two parts of the process are balanced to ensure a constant bone density. If this balance is not maintained, bone structure, mass and strength may be altered. Osteoporosis is a disease of bone in which bone mineral density is reduced, as a result of increased bone breakdown and/or reduced bone renewal. Osteoporosis is thought to be responsible for 200,000 fractures every year, with broken wrists, hips and spinal bones the most common. The measurement of products in the blood or urine as a result of either bone breakdown or renewal, can be used to monitor bone turnover. These tests therefore, may be useful in monitoring the response to treatment of bone turnover in patients with osteoporosis.
The primary aims of this technology assessment are to evaluate how well changes in bone turner markers correlate with reductions in the incidence of fractures in people being treated for osteoporosis, and how the use of bone turnover markers impacts on adherence with osteoporosis treatment. The cost-effectiveness of using bone turnover markers to encourage adherence to treatment, and identifying patients who are not adherent will also be investigated.
This project has now been completed and a report will be issued.Conducted by: Jane Burch1, Dawn Craig1, Aileen Neilson1, Steve Rice1, Lisa Stirk1 and Huiqin Yang1
1. The Centre for Reviews and Dissemination
Further detailsProject page on NIHR HTA Programme website
Commissioned by the NIHR HTA Programme as part of the Technology Assessment Report (TAR) process